Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Status:
Recruiting
Trial end date:
2024-01-23
Target enrollment:
Participant gender:
Summary
A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as
Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors